Isosteviol derivative as well as preparation method and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of isosteviol and its derivatives, which is applied in the field of isosteviol derivatives and its preparation, can solve the problems of high cardiovascular risk and achieve good cardioprotective activity and the effect of protecting death and injury
Active Publication Date: 2021-07-13
GUANGDONG UNIV OF TECH
View PDF6 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Although including statins, angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers (BBs), angiotensin II type 1 receptor blockers (ARBs) and aldosterone receptor blockers (AIRBs) Several groups of cardioprotective drugs, including , have been shown to be effective in reaching hard endpoints, but treatment of hypertension with these drugs reduces mortality by no more than 30%, and the residual cardiovascular risk remains quite high
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0054] This example provides a series of isosteviol derivatives, prepared according to the following two synthetic routes:
[0055] Synthetic route one:
[0056] Reaction conditions and reagents: (a) NaOH, (HCHO)n , EtOH, reflux; (b) Ac 2 O, Pyridine, DMAP for 3a; (c) Acid, DMAP, EDCI, DCM for 3b-3n; (d) PDC, DMF, rt.)
[0057]
[0058] Synthetic route two:
[0059] Reaction conditions and reagents: (a) DPPA, Et 3 N, t BuOH, reflux; (b) Acid, DMAP, EDCI, DCM; (c) PDC, DMF.
[0060]
[0061] Specifically, the preparation method of each compound comprises the following steps:
[0062] (1) Synthesis of Compound 2
[0063] Isosteviol (50mg, 0.2mmol), sodium hydroxide (31.4mg, 0.8mmol) and paraformaldehyde (37.8mg, 1.3mmol) were dissolved in absolute ethanol (2mL), the mixture was stirred at 80°C, and the reaction 5h. The mixture was diluted with ethyl acetate, neutralized with hydrochloric acid (1N), the solution was washed with saturated brine, dried over anhydrous ...
Embodiment 2
[0195] This example is a zebrafish experiment on a series of isosteviol derivatives prepared in the example, and the cardiac activity of the isosteviol derivatives of the present invention is evaluated through the zebrafish experiment.
[0196] (1) Breeding of zebrafish and collection of embryos: buy zebrafish (3-12 months old) from the National Zebrafish Resource Center, and raise them in a mobile culture with a photoperiod of 14:10h (light: dark) and a temperature of 28.5±1°C Breeding in the box, feeding with live brine shrimp twice a day; mating of zebrafish (female:male=1:1), collecting embryos, washing with Holt Buffer buffer, and culturing in an incubator (28.5±1°C) for 24h , screened by microscopic examination.
[0197](2) DOX-induced zebrafish embryonic heart failure model for drug screening: 24hpf wild-type zebrafish embryos were allocated to 24-well plates (20 embryos / well), and 1 mL of DOX (100 μM) and various test compounds (5 , 15, 40μM), treated for 72h, observe...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to an isosteviol derivative as well as a preparation method and application thereof. The isosteviol derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification. In the formula (I), R1 is selected from a hydroxyl group or a carbonyl group; R2 is selected from H, a C1-5 saturated straight-chain alkyl group, a C3-6 saturated cyclic alkyl group, a pyridine ring, a phenyl group, a benzyl/substituted benzyl group, a phenethyl/substituted phenethyl group and phenylpropyl/substituted phenylpropyl group; and R3 is selected from a carboxyl group or primary amine. According to the isosteviol derivative, specific active sites of isosteviol are specifically modified, the obtained derivative has good heart protection activity, and the isosteviol derivative mainly prevents death and damage of myocardial cells by inhibiting excessive generation of active oxygen, recovering the potential of a mitochondrial membrane and maintaining mitochondrial morphology.
Description
technical field [0001] The present invention relates to the fields of drug design and medicinal chemistry, and more specifically relates to an isosteviol derivative and its preparation method and application. Background technique [0002] Cardiovascular disease (CVDs) is the disease with the highest mortality rate in the world. About 17.9 million people die from cardiovascular disease every year, accounting for 31% of the death toll in the world. Cardioprotective drugs can protect the metabolism, structure and function of the heart and blood vessels, and reduce their damage in primary or secondary prevention, and are extremely important in the treatment of patients with cardiovascular disease or high risk of cardiovascular disease. Although including statins, angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers (BBs), angiotensin II type 1 receptor blockers (ARBs) and aldosterone receptor blockers (AIRBs) Several groups of cardioprotective drugs, including , have...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more